SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
WhiteHawk Minerals redeemed all outstanding Series D Preferred Stock for approximately $39.9 million on June 10, 2026. This significant capital event materially affects the rights and economic interests of preferred shareholders and represents a substantial use of capital in connection with the company's public offering.
View raw filing on EDGAR →WhiteHawk Minerals created direct financial obligations through an amendment to a revolving credit facility and a change in issuer under a note purchase agreement in connection with its internalization and public offering. The specific nature and materiality of these obligations depend on whether they involve debt covenant modifications, equity dilution, or other triggering events.
View raw filing on EDGAR →WhiteHawk Minerals amended its Certificate of Incorporation and Bylaws effective June 10, 2026 in connection with its public offering. The disclosure provides limited substantive detail about the specific provisions altered, though the amendments are material to the company's governance structure in connection with going public.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from the 2026 annual meeting held on June 9, 2026, reporting the election of James Gertie as a Class I director with 30,503,999 votes for and 63,545 votes withheld. The filing directly corresponds to Item 5.07 requirements and constitutes a material corporate governance event affecting the composition of the board of directors.
View raw filing on EDGAR →American Eagle entered into Amendment No. 2 to its $700 million ABL Credit Agreement, extending the maturity date from June 2027 to June 2031 and restructuring interest rate terms. This material amendment to a significant credit facility affects the company's debt structure and financial flexibility.
View raw filing on EDGAR →BancFirst Corporation entered into an agreement to acquire Spirit BankCorp, Inc. and SpiritBank, a community bank with approximately $939.6 million in total assets. This is a material acquisition that would significantly affect the registrant's financial position and operations. Although disclosed under Item 7.01 (Regulation FD Disclosure) rather than the typical Item 1.01, the substance is clearly a material M&A transaction requiring classification as ma_activity.
View raw filing on EDGAR →Syndax issued $250 million of convertible senior notes in a private placement on June 10, 2026, with net proceeds of approximately $243 million, creating potential equity dilution of up to 13,631,400 shares upon conversion. The offering was conducted under Section 4(a)(2) of the Securities Act as an unregistered private placement to certain investors.
View raw filing on EDGAR →Tectonic Therapeutic held its 2026 Annual Meeting of Shareholders on June 8, 2026, with voting results disclosed on three proposals: election of Class II directors Timothy A. Springer and Stefan Vitorovic, ratification of Deloitte & Touche LLP as independent auditor, and advisory approval of executive compensation. All three proposals passed with substantial majorities.
View raw filing on EDGAR →The company announced completion of enrollment in the Phase 2 TX45 APEX clinical trial for a therapeutic candidate targeting pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF). This represents a significant clinical development milestone for the company's pipeline.
View raw filing on EDGAR →Tango Therapeutics entered into an underwriting agreement on June 9, 2026 to conduct an underwritten public offering of 18.2 million shares of common stock and pre-funded warrants to purchase 1.8 million additional shares, with a 30-day overallotment option for 3 million more shares. The offering is expected to raise approximately $566.5 million in net proceeds. This is a material dilutive equity issuance that increases the share count and dilutes existing shareholders, disclosed under Item 1.01 as a material definitive agreement.
View raw filing on EDGAR →PureCycle Technologies executed an Eleventh Amendment to its Credit Agreement on June 10, 2026, materially modifying its $200 million revolving credit facility to permit upcoming equity offerings and remove certain secured obligations, restructuring the Company's capital and financing arrangements.
View raw filing on EDGAR →PureCycle Technologies announced its intention to conduct concurrent underwritten public offerings of $250 million in convertible senior notes and $145 million in common stock, representing a material dilutive equity issuance to raise capital.
View raw filing on EDGAR →The filing discloses a "previously announced proposed business combination" between Crown PropTech Acquisitions (SPAC) and Mkango Rare Earths Limited, with contemplated private capital raises through equity and debt securities. The disclosure describes ongoing financing activities, investor meetings, and a filed Form F-4 registration statement in furtherance of the business combination, which constitutes material M&A activity under Item 7.01 (Regulation FD Disclosure).
View raw filing on EDGAR →Rafael Holdings announced completion of the final 96-week study visit in its pivotal Phase 3 TransportNPC™ study for Trappsol® Cyclo™ in Niemann-Pick Disease Type C, with topline data expected in H2 2026. This represents a material clinical milestone for the company's lead therapeutic candidate.
View raw filing on EDGAR →The filing discloses entry into two non-binding letters of intent: (1) a proposed $5.0 million convertible preferred stock investment from an investor, and (2) a proposed sale of a portion of the operating business for approximately $6.0 million in cash plus assumption of up to $3.0 million in liabilities. These constitute material acquisition and disposition activity under Items 1.01/1.02 that would affect a reasonable investor's assessment of the company's strategic direction and capital structure, despite the non-binding nature of the LOIs.
View raw filing on EDGAR →La Rosa Holdings Corp. issued Series D Preferred Stock to an investor under Rule 506(b) of Regulation D, a private placement exemption for unregistered equity securities. This dilutive issuance materially affects existing shareholders' ownership percentages and signals capital-raising activity.
View raw filing on EDGAR →This disclosure announces the Company's intent to enter into Non-Redemption Agreements with unaffiliated shareholders in connection with an extraordinary general meeting to approve an extension of time to complete an initial business combination. The agreements would incentivize shareholders not to redeem their Class A shares by offering Class B shares from the Sponsor at a negotiated ratio. While this involves shareholder voting mechanics and potential dilutive equity issuances, the core event is the announcement of a material transaction structure (non-redemption agreements with equity consideration) that affects the capital structure and shareholder base, which does not fit cleanly into the more specific categories but is clearly material to investors assessing the Company's path to completing a business combination.
View raw filing on EDGAR →Mountain Lake Acquisition Corp. announced a postponement of its extraordinary general meeting from an unspecified earlier date to June 16, 2026, to allow additional time to complete its business combination with Avalanche Treasury Corporation. While the postponement itself is administrative, the underlying business combination approval and the extension of the deadline to consummate the transaction (from June 16 to September 16, 2026) are material to shareholders' assessment of the SPAC's ability to close its transaction. This does not fit neatly into ma_activity (which typically covers entry, completion, or termination of M&A) since the business combination was already approved on June 4, 2026, and this disclosure concerns only a procedural postponement and timeline extension rather than a new M&A event.
View raw filing on EDGAR →This disclosure reports the consummation of Keystone Acquisition Corp.'s IPO on June 4, 2026, generating $287.5 million in gross proceeds from 28.75 million units, plus a concurrent private placement of 8.47 million warrants for $8.47 million. While the IPO itself is a material capital-raising event, the filing is structured as Item 8.01 (Other Events) rather than Item 2.01 (Completion of Acquisition or Disposition) or a dedicated IPO item, and the disclosure focuses on confirming previously reported facts rather than announcing new material developments. The event is material to investors but does not fit cleanly into the earnings_release, ma_activity, or dilutive_issuance categories as typically understood in the taxonomy.
View raw filing on EDGAR →Eureka Acquisition Corp entered into a material definitive agreement with Marine Thinking to effect a business combination, including the issuance of an unsecured promissory note (Extension Note) for $150,000 to fund a one-month extension of the business combination deadline, with conversion rights into private units upon completion of the merger.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from Purple Innovation's Annual Meeting held on June 9, 2026. The filing presents detailed vote tallies for three proposals: election of eight directors, advisory approval of named executive officer compensation, and ratification of BDO USA, LLP as independent auditor. Item 5.07 is the designated 8-K item for shareholder vote results, and the prose directly reports the voting outcomes with vote counts for each director and proposal.
View raw filing on EDGAR →BlockchAIn Digital Infrastructure completed a public offering of 33,333,334 shares at $1.65 per share on June 8, 2026, raising approximately $51.4 million in net proceeds and issuing 1,333,333 Representative Warrants to the underwriter. This substantial equity issuance represents a material dilutive capital raise affecting existing shareholder ownership and the company's financial position.
View raw filing on EDGAR →Getty Images discloses an adverse court decision in Funicular Funds LP v. Getty Images Holdings, Inc., with the court granting summary judgment to plaintiffs on warrant breach claims and directing entry of judgment for approximately $67.8 million plus pre-judgment interest. This material litigation outcome—a judicial determination of liability and damages—directly affects the company's financial position and has been reserved against on the balance sheet, making it a significant material event requiring disclosure under Item 8.01.
View raw filing on EDGAR →The filing discloses Item 5.07 results from Ramaco Resources' Annual Meeting of Shareholders held on June 10, 2026, including voting outcomes on four proposals: election of three directors (Bryan H. Lawrence, David E.K. Frischkorn Jr., and Michael R. Graney), ratification of Grant Thornton LLP as independent auditor, approval of a 4,000,000-share increase to the Long-Term Incentive Program, and advisory approval of named executive officer compensation. All proposals passed with substantial majorities, representing material governance and compensation decisions.
View raw filing on EDGAR →The filing discloses that Ribbon Acquisition Corp. regained compliance with Nasdaq Listing Rule 5250(f) following payment of a past due fee balance, resolving a non-compliance matter previously disclosed on June 5, 2026. While the company has now cured the violation, the disclosure of a listing rule breach and its resolution is material to investors assessing continued listing status and regulatory standing. The delisting_risk classification captures the materiality of listing compliance events, even when resolved.
View raw filing on EDGAR →The disclosure announces a postponement of the extraordinary general meeting scheduled to vote on a proposed business combination between M3-Brigade Acquisition V Corp. and ReserveOne, Inc., moving the vote from June 15 to June 18, 2026, and extending the shareholder redemption deadline. While this is a material event affecting shareholders' ability to vote on and redeem shares in connection with a significant M&A transaction, it is procedural in nature (a meeting postponement) rather than a substantive change to the business combination itself. The event does not fit neatly into the ma_activity category (which covers entry, completion, or termination of M&A) or shareholder_vote_results (which covers actual vote outcomes), making other_material the most appropriate classification.
View raw filing on EDGAR →The filing discloses an extension of byNordic's business combination deadline from June 12, 2026 to July 12, 2026, funded by a $17,470 deposit into the Trust Account. This is a material event for a SPAC as it directly affects the timeline for completing the initial business combination and the company's continued existence. While not a traditional M&A completion, the extension is a critical milestone event that would affect investor assessment of the registrant's prospects and timeline.
View raw filing on EDGAR →The filing discloses an unregistered sale of limited partnership units totaling approximately $89.55 million under Item 3.02, with Class I and Class E units sold to accredited investors and qualified purchasers pursuant to Section 4(a)(2) and Regulation D. This is a classic dilutive equity issuance by a fund that would materially affect existing unitholders' ownership percentages and is a core disclosure event for private fund offerings.
View raw filing on EDGAR →Aditxt entered into a Business Combination Agreement dated June 10, 2026, whereby its subsidiary Ignite Proteomics LLC will merge with Copley Acquisition Corp (SPAC) in a two-step transaction resulting in Ignite becoming a wholly-owned subsidiary of the resulting public company (Pubco), with merger consideration of $150 million in Pubco common stock.
View raw filing on EDGAR →Presidio Production Company entered into a material definitive agreement on June 9, 2026, whereby its subsidiary Presidio Finance LLC issued $350 million in aggregate principal amount of asset-backed securities (ABS III Notes) in a private offering under Section 4(a)(2). While this is technically a debt issuance rather than a traditional M&A transaction, the Item 1.01 classification and the materiality of the $350 million financing—which refinances existing debt and provides capital for general corporate purposes—makes this a material capital structure event. The transaction involves entry into a definitive indenture agreement governing the ABS III Notes and represents a significant financing activity material to investors.
View raw filing on EDGAR →The filing discloses the appointment of Erik Blum as President effective June 1, 2026, with a detailed employment agreement specifying $200,000 base salary, $50,000 restricted stock grant, and up to 20% performance bonus. While the section also mentions Patricia Kaelin's dismissal as CFO, the primary focus and substantive disclosure centers on Blum's appointment and compensatory arrangements. This is material as it represents a significant executive appointment with detailed compensation terms affecting the company's leadership structure.
View raw filing on EDGAR →EBR Systems entered into an underwriting agreement for a fully underwritten A$150.0 million capital raise through the sale of approximately 394.7 million new CDIs (representing new shares) to institutional and retail investors on the ASX, comprising an institutional placement and pro rata entitlement offer that will dilute existing shareholders.
View raw filing on EDGAR →The filing explicitly discloses an "Earnings Release announcing its Fiscal 2026 fourth quarter and year-end financial results for the quarter and year ended March 31, 2026" under Item 2.02 (Results of Operations and Financial Condition), with the release attached as Exhibit 99.1. This is a standard earnings release disclosure.
View raw filing on EDGAR →This Item 5.07 disclosure presents the results of ImmunityBio's 2026 Annual Meeting of Stockholders held on June 9, 2026, including voting outcomes for the election of nine directors and ratification of Deloitte & Touche LLP as independent auditor. The filing directly matches the shareholder_vote_results event type, which covers results of votes at annual or special meetings of security holders. These outcomes are material to investors as they confirm the composition of the board and auditor selection.
View raw filing on EDGAR →Crocs held its Annual Meeting of Stockholders on June 9, 2026, with shareholders voting on four matters: election of Class III directors (Smach, Kaplan, Tolmare), ratification of Deloitte & Touche LLP as auditor, advisory approval of named executive officer compensation, and approval of the 2026 Equity Incentive Plan. All proposals passed with substantial majorities.
View raw filing on EDGAR →Craig Saldanha resigned as Chief Product Officer after four years in the role, representing a departure of a named executive officer in a C-suite position.
View raw filing on EDGAR →Yelp held its Annual Meeting of Stockholders on June 5, 2026, with certified voting results on four proposals: election of nine directors, ratification of Deloitte & Touche LLP as independent auditor, advisory approval of named executive officer compensation, and approval of the Restated ESPP.
View raw filing on EDGAR →Kiora Pharmaceuticals held its Annual Meeting on June 10, 2026, with shareholders voting on four proposals: election of three Class II Directors (Lisa Walters-Hoffert, Aron Shapiro, and Praveen Tyle, Ph.D.), a non-binding advisory vote on named executive officer compensation, ratification of Haskell & White LLP as independent auditor, and approval of a 1,500,000 share increase to the 2024 Equity Incentive Plan. All four proposals passed.
View raw filing on EDGAR →The disclosure centers on the Board's approval and appointment of Todd Diganci as a director effective August 1, 2026, expanding the Board from nine to ten members. While the section also mentions standard director compensation arrangements, the principal disclosed action is the appointment of a new director with significant financial and regulatory experience (former FINRA EVP/CFO/CAO), making this an exec_appointment event. The appointment is material as it affects Board composition and governance.
View raw filing on EDGAR →This is Item 5.07 disclosing the final voting results from Aquestive Therapeutics' 2026 Annual Meeting of Stockholders held on June 10, 2026. The filing presents tabulated results for three matters: election of Class II directors (Gregory B. Brown, John S. Cochran, and Abigail L. Jenkins), advisory approval of executive compensation, and ratification of KPMG LLP as independent auditor. This is a standard shareholder vote results disclosure that is material to investors as it confirms governance outcomes and auditor appointment.
View raw filing on EDGAR →The disclosure announces commencement of field operations for a planned sidetrack phase of the Megiddo-Jezreel #2 well in Israel, including re-entry, drilling out a temporary plug, wellbore conditioning, and horizontal sidetrack drilling. While this represents a material operational milestone for an exploration company with active petroleum operations, it does not fit neatly into the more specific event categories (not an earnings release, executive change, M&A activity, impairment, or other defined event types). The operational progress on a material exploration project would affect a reasonable investor's assessment of the company's execution and prospects.
View raw filing on EDGAR →CervoMed entered into a securities purchase agreement for a private placement of 3,360,377 units comprising common stock (or pre-funded warrants) and Series B and C warrants, generating approximately $10.5 million in gross proceeds with potential additional $21.7 million upon warrant exercise. The unregistered securities are subject to resale restrictions, with significant insider participation from the CEO, Chair, and Director. Proceeds will be used for R&D and operations.
View raw filing on EDGAR →CervoMed disclosed entry into a Purchase Agreement and provided business updates via press release on June 10, 2026, including Strategic Pipeline Priorities. The specific terms and financial impact of the Purchase Agreement are not detailed in the filing excerpt, preventing confident classification as a more specific event type such as M&A activity.
View raw filing on EDGAR →The Company is announcing an irrevocable election to redeem outstanding warrants (CUSIP # 74587B143) issued in a July 2024 rights offering. The redemption is triggered by the stock price reaching 200% of the exercise price ($22.00) for 20 consecutive trading days, with warrants redeemable for $0.01 per share by July 13, 2026. While this is a warrant redemption event that affects security holders, it does not fit neatly into the more specific categories (not a dilutive issuance, not M&A, not an impairment). The event is material as it affects the rights and economic interests of warrant holders and the capital structure of the Company.
View raw filing on EDGAR →Orchid Island Capital held its 2026 Annual Meeting of Stockholders with voting results on four proposals: election of six directors, ratification of BDO USA as independent auditor, advisory approval of named executive officer compensation, and advisory frequency recommendation for future compensation votes.
View raw filing on EDGAR →The company announced a monthly dividend of $0.10 per share and disclosed portfolio details as of May 31, 2026, including RMBS portfolio information and other operational metrics.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure of shareholder vote results from the 2026 annual meeting held on June 10, 2026. The filing reports voting outcomes on three matters: election of Class II directors (Michael Earley and Veronica Hill-Milbourne), ratification of PricewaterhouseCoopers LLP as independent auditor, and advisory approval of named executive officer compensation. The detailed vote tallies (For, Against, Abstain, Broker Non-Votes) for each proposal are the hallmark of shareholder_vote_results classification.
View raw filing on EDGAR →ImmuCell's Board authorized a significant manufacturing capacity expansion program involving ~$3.5 million in Phase 1 capital investment and strategic repurposing of facilities to shift from Re-Tain® to First Defense® production. This represents a material strategic and operational decision affecting the company's manufacturing footprint and capital allocation, but does not fit neatly into the standard 8-K event taxonomy (not M&A, not an impairment, not an executive change). The disclosure is material to investors assessing the company's growth strategy and capital deployment.
View raw filing on EDGAR →Item 2.02 is the standard location for disclosure of quarterly or annual financial results. The filing date of 2026-06-10 and Item 2.02 designation indicate this section contains an earnings release or results of operations disclosure, which is material to investors' assessment of the company's financial performance.
View raw filing on EDGAR →Molina Healthcare announced that the Illinois Department of Healthcare and Family Services intends to award a HealthChoice Illinois Medicaid Managed Care program contract to its Illinois subsidiary. This is a material contract award that would affect the registrant's revenue and business operations, but it does not fit neatly into the standard M&A, earnings, or executive event categories. The disclosure is made under Regulation FD (Item 7.01), indicating it is material information being disclosed to investors.
View raw filing on EDGAR →